Search Results

Home → Flash News → What are your thoughts on β2AR? Listen to Ep.163 of the @DrGPCR Podcast, where @DVeprintsev shares his thoughts and experiences about working with GPCRs, tips on framing your research correctly, and other insightful topics. Don’t miss out! ✳️https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #GPCRs #SciencePodcast #DrugDiscovery #Biotech #DrGPCR Published on April 3, 2025 Category Dr. GPCR Podcast What are your thoughts on β2AR? Listen to Ep.163 of the @DrGPCR Podcast, where @DVeprintsev shares his thoughts and experiences about working with GPCRs, tips on framing your research correctly, and other insightful topics. Don’t miss out! ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #GPCRs #SciencePodcast #DrugDiscovery #Biotech #DrGPCR Previous Next Recent Articles

Learn why some inhibitors act long after dosing ends. Explore the kinetic principles behind persistent binding and smarter drug design. Home → Flash News → irreversible drugs post 2 Persistent binding ≠ just covalent. Published on October 24, 2025 Category Terry's Corner Why do some inhibitors act long after the drug itself is gone? It’s not always about covalent chemistry — often, it’s about kinetics. Irreversible interactions emerge when one simple imbalance tips the scale: inflow outpacing outflow. That’s why a compound like phenoxybenzamine can knock down receptor populations after just a brief exposure. And why slow-dissociating allosteric inhibitors can reshape signaling curves for hours — or even days — after dosing stops. When persistent binding meets structured tissues, this effect can amplify or collapse. High-affinity molecules can get trapped at the periphery of a tumor, never reaching the core. The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure. This isn’t a subtle nuance. Binding kinetics are a design variable, as critical as potency or clearance. Get it wrong, and the best molecule on paper stalls in development. Get it right, and you unlock durable efficacy with leaner dosing strategies. If your discovery strategy still treats kinetics as an afterthought, you’re already behind. ✳️ Read More: https://www.ecosystem.drgpcr.com/post/beyond-clearance-the-strategic-power-of-irreversible-drug-binding #GPCR #DrGPCR #Pharmacology #DrugDiscovery #BindingKinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDesign Previous Next Recent Articles

Home → Flash News → insights into g protein coupling preference from cryo em structures of gq bound PTH1R Published on July 14, 2025 Category GPCR Weekly News What drives Gq vs. Gs selectivity at PTH1R? This new Nature Chemical Biology paper reveals cryo-EM structures of Gq-bound PTH1R—highlighting how N-linked glycans and ICL2 interactions stabilize receptor conformations that favor Gq coupling. ♦️ Two distinct Gq-bound conformations ♦️ Comparison with Gs-bound PTH1R ♦️ Strategic implications for biased agonist design A critical advance for anyone working on class B1 GPCRs, bone biology, or biased signaling. ➡️ Read the paper: https://www.nature.com/articles/s41589-025-01957-6?utm_content=buffer3b1fa&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer #DrGPCR #GPCR #PTH1R #BiasedAgonism #CryoEM #Pharmacology #Osteoporosis #DrugDiscovery Previous Next Recent Articles

Home → Flash News → In case you haven’t heard, our next Dr.GPCR University course is open for registrations 🙂 Learn about "The Practical Assessment of Signaling Bias" with Dr. Terry Kenakin. 🙌 Hands-on exercises included! ✳️Only 25 spots available ➡️Enjoy a 25% discount with your Premium Membership https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on January 24, 2025 Category GPCR University In case you haven’t heard, our next Dr.GPCR University course is open for registrations 🙂 Learn about "The Practical Assessment of Signaling Bias" with Dr. Terry Kenakin. 🙌 Hands-on exercises included! ✳️Only 25 spots available ➡️Enjoy a 25% discount with your Premium Membership https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → Game-changer for GPCR research! 🔬🧪 Molecular glues offer a new way to fine-tune receptor signaling, opening doors for next-gen drug discovery Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/reviews/molecular-glues%3A-a-new-approach-to-modulating-gpcr-signaling-bias #gpcr #drgpcr Published on February 17, 2025 Category GPCR Weekly News Game-changer for GPCR research! 🔬🧪 Molecular glues offer a new way to fine-tune receptor signaling, opening doors for next-gen drug discovery Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https:// www.ecosystem.drgpcr.com/reviews/molecular-glues%3A-a-new-approach-to-modulating-gpcr-signaling-bias #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → This study adds a key piece to the puzzle of adhesion GPCR signaling. Understanding receptor-specific nuances, like the role of NTF cleavage, is crucial for decoding their functional outcomes. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️https://www.ecosystem.drgpcr.com/adhesion-gpcrs/n-terminal-fragment-shedding-contributes-to-signaling-of-the-full-length-adhesion-receptor-adgrl3 #gpcr #drgpcr Published on January 28, 2025 Category GPCR Weekly News This study adds a key piece to the puzzle of adhesion GPCR signaling. Understanding receptor-specific nuances, like the role of NTF cleavage, is crucial for decoding their functional outcomes. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️ https:// www.ecosystem.drgpcr.com/adhesion-gpcrs/n-terminal-fragment-shedding-contributes-to-signaling-of-the-full-length-adhesion-receptor-adgrl3 #gpcr #drgpcr Previous Next Recent Articles

Applying Pharmacology to Drug Discovery Dr. Terry Kenakin Get Started Premium Members benefits: - Subscribe and save 25% on every GPCR Course - Early-bird access - Recordings will be available < Back to GPCR courses Watch recording Your Instructor Dr. Terry Kenakin

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Breakfast 2 Date & Time Saturday, November 4th / 7:30 AM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Home → Flash News → Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Published on June 3, 2025 Category Dr. GPCR Podcast Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Previous Next Recent Articles

A collaboration between chemistry and biology sparked a GPCR imaging breakthrough, leading to new chemical probes for GLP-1R visualization in real tissue. Home → Flash News → A GPCR imaging breakthrough that didn’t start in a grant proposal A GPCR imaging breakthrough that didn’t start in a grant proposal Published on December 3, 2025 Category It started with a cold email. A young chemist, Dr. Johannes Broichhagen, was asked if he could synthesize a molecule “when you’re back in Munich.” That small moment pulled him into islet biology, confocal imaging, and a collaboration that would reshape how GLP-1R is visualized in real tissue. The new blog takes you behind the scenes — the London trip, the early confocal experiments, the pivot to chemical probes, and the trust-driven partnership that sparked a new era in GPCR imaging. If you care about chemical biology, receptor visualization, or building tools that actually work in complex systems, this one is worth reading. 🔗 Read the full story : https://www.ecosystem.drgpcr.com/post/how-collaboration-sparked-a-gpcr-imaging-breakthrough-in-chemical-biology Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Discover how Dr. Jens Carlsson’s lab at Uppsala University is redefining GPCR drug discovery with predictive molecular modeling that forecasts receptor behavior—before the first assay begins. Home → Flash News → ep 175 with jens carlsson clip 1 Can your model actually predict the outcome of a GPCR experiment? Published on October 27, 2025 Category Dr. GPCR Podcast “Explain” is no longer enough. Can your model actually predict the outcome of a GPCR experiment? At Uppsala University, Dr. Jens Carlsson and his team are redefining what computational modeling means in drug discovery. Their lab doesn’t just simulate receptor-ligand interactions after the fact; they aim to forecast receptor behavior before the first assay is run. By integrating molecular docking, molecular dynamics, and machine learning, they design ligands with the goal to anticipate biological outcomes. This kind of predictive modeling challenges the traditional role of computation in pharmacology, where models have too often served as post hoc rationalizations. But Carlsson’s lab stands out for another reason: knowing when not to predict. His team is candid about the limits of their models. If the resolution isn't good enough, or if the data is too uncertain, they’re not afraid to say, “We don’t know.” That scientific humility (combined with deep collaborations with medicinal chemists and pharmacologists) is exactly what makes their predictions so useful. This episode is essential listening for anyone thinking seriously about translational pharmacology and the future of GPCR drug discovery. 🎧 Explore how predictive modeling is reshaping GPCR science in this Dr. GPCR Podcast episode: model predict discover #DrGPCR #GPCR #MolecularModeling #PredictivePharmacology #DrugDiscovery Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → Unlock your pharmacology potential with Terry’s Corner. No fluff. Just clear, on-demand insight from Dr. Terry Kenakin—built for scientists at every level. 🟢 Building core expertise? Learn dose-response, agonism, binding, bias, kinetics, and the models that build real confidence. 🟢 Driving drug discovery? Apply pharmacology to selectivity, ADME, early safety, and smarter decision-making. 🟢 Already a drug hunter? Sharpen your edge with allosteric modulation, residence time, molecular dynamics, and translational PK/PD. Learn on-demand. Apply immediately. Early access begins July 1 → https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining Published on June 28, 2025 Category Terry's Corner Unlock your pharmacology potential with Terry’s Corner. No fluff. Just clear, on-demand insight from Dr. Terry Kenakin—built for scientists at every level. 🟢 Building core expertise? Learn dose-response, agonism, binding, bias, kinetics, and the models that build real confidence. 🟢 Driving drug discovery? Apply pharmacology to selectivity, ADME, early safety, and smarter decision-making. 🟢 Already a drug hunter? Sharpen your edge with allosteric modulation, residence time, molecular dynamics, and translational PK/PD. Learn on-demand. Apply immediately. Early access begins July 1 → https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining Previous Next Recent Articles

Home → Flash News → Forget one receptor at a time. Go big.Ep.167 of the Dr.GPCR Podcast with Tom Sakmar & Ilana Kotliar is about scaling GPCR research with multiplexing, miniaturization, and collaboration. The tools are built. The data is free. What will you ask next? 📲 Dive in: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRtraining #GPCRresearchcommunity #DrGPCR #GPCRdata Published on June 5, 2025 Category Dr. GPCR Podcast Forget one receptor at a time. Go big.Ep.167 of the Dr.GPCR Podcast with Tom Sakmar & Ilana Kotliar is about scaling GPCR research with multiplexing, miniaturization, and collaboration. The tools are built. The data is free. What will you ask next? 📲 Dive in: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRtraining #GPCRresearchcommunity #DrGPCR #GPCRdata Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma Date & Time Friday, November 3rd / 4:20 PM About Victoria Rasmussen "Victoria Rasmussen is a graduate fellow in Dr. Thomas Sakmar’s laboratory at Rockefeller University, where she studies the signaling and degradation of G protein-coupled receptors. She completed her undergraduate education at Providence College, receiving a B.S. in Biology and a B.A. in Psychology. During her time at Providence College, she received the Walsh Grant Fellowship to develop novel methods of synthesizing 2-imidazoline scaffolds to be used as proteasome modulators in the laboratory of Travis Bethel. Victoria started her Ph.D. at the Tri-Institutional Ph.D. program in Chemical Biology, where she joined the lab of Thomas Sakmar at Rockefeller University. She is currently working to understand the signaling and degradation of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic strategy. " Victoria Rasmussen on the web Tri-Institutional PhD Program Chemical Biology LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Discover how enzyme inhibition can enhance drug discovery strategies. Explore inhibition modes, CYP450 allostery, and insights from Dr. Eric Trinquet in this week's news. Home → Flash News → Weekly News October 16 Published on October 16, 2025 Category GPCR Weekly News Enzymes decide which molecules get a real shot at efficacy. This week’s Weekly News is your practical guide to building enzyme inhibition into discovery—not as a checkbox, but as a strategy. We unpack inhibition modes (competitive, noncompetitive, mixed, uncompetitive), the messy truth of CYP450 allostery and DDIs, and why allosteric control can protect potency in substrate-rich environments. Plus: a mindset masterclass from Dr. Eric Trinquet —how structured play turns into assays and why serendipity belongs in your build process. And a tertiary read on ciliary micro-domains linking OPN3/MCR signaling to appetite and skin biology. Read the full Weekly News ➤ https://lnkd.in/eWkAphen If this helped, pass it along to a colleague who needs the signal. #DrGPCR #GPCR Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Dinner 2 Date & Time Friday, November 3rd / 7:00 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer: Novel Precision Targeted and Immunotherapies Date & Time Friday, November 3rd / 3:30 PM Abstract Coming Soon About J. Silvio Gutkind "Dr. Gutkind is a Distinguished Professor and Chair of the Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer Center, University of California San Diego (UCSD). He served as Branch Chief at NIDCR, NIH, since 1998 until his recruitment to UCSD in 2015. His research team has pioneered the study of G proteins and G protein coupled receptors (GPCRs) in human malignancies. He is exploiting the emerging information on dysregulated signaling circuitries and individual genomic and molecular alterations to develop new precision cancer treatments, and to identify novel multimodal strategies to enhance the response to cancer immunotherapies." J. Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Pubmed LinkedIn Twitter UCSD Moores Cancer Center Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Principles of Pharmacology in Drug Discovery II Dr. Terry Kenakin Get Started Premium Members benefits: - Subscribe and save 25% on every GPCR Course - Early-bird access - Recordings will be available < Back to GPCR courses Watch recording Your Instructor Dr. Terry Kenakin

Explore how chemical probes enable real-time GLP-1R visualization in cells and tissues. Episode 2 reveals new GPCR imaging strategies and tool design insights. Home → Flash News → Visualizing GPCRs in their native environment changes everything Visualizing GPCRs in their native environment changes everything Published on December 2, 2025 Category This week on The Dr. GPCR Podcast , we bring you Episode 2 of our three-part series with Celtarys Research — featuring chemist Dr. Johannes Broichhagen , whose work is redefining how we image GPCRs in real tissue. His team’s chemical probes enabled high-resolution GLP-1R visualization across systems — from pancreatic islets to in vivo two-photon imaging. Inside the episode: Chemical probes vs antibodies: specificity, stability, and live-cell performance Mapping GPCR surface pools with precision Tissue-level insights reshaping metabolic disease research What’s next: multiplex receptor labeling + AI-designed tools If GLP-1R biology, receptor trafficking, or advanced imaging are part of your work, this conversation belongs on your radar. 🎧 Listen to Episode 2 → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/chemical-probes-for-gpcr-imaging-and-internalization And stay tuned for Episode 3 with Celtarys. #GPCR #DrGPCR #metabolism #GLP1R #receptorbiology #fluorescenceimaging #drugdiscovery Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → 🔥 New Course Alert! “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! Spots are filling up fast—Premium Members get 25% off! This advanced course is exclusively available in the Ecosystem, so don’t miss your chance to learn from the best. 🔹 Secure your spot now! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr #pharmacolgy #drugdiscovery #research Published on February 24, 2025 Category Dr. GPCR Courses 🔥 New Course Alert! “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! Spots are filling up fast—Premium Members get 25% off! This advanced course is exclusively available in the Ecosystem, so don’t miss your chance to learn from the best. 🔹 Secure your spot now! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr #pharmacolgy #drugdiscovery #research Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → A complete profile = a complete YOU. Highlight your publications, skills, and interests to connect with the right people! ✳️Go to https://www.ecosystem.drgpcr.com/account/my-account and update your profile on the Dr.GPCR. #gpcr #drgpcr Published on February 5, 2025 Category Dr. GPCR Profiles A complete profile = a complete YOU. Highlight your publications, skills, and interests to connect with the right people! ✳️Go to https://www.ecosystem.drgpcr.com/account/my-account and update your profile on the Dr.GPCR. #gpcr #drgpcr Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

No plans available Once there are plans available for purchase, you’ll see them here.

Home → Flash News → In case you haven’t heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic Drugs,” with Dr. Terry Kenakin 👏 Spots are filling up fast, run and save yours, and enjoy a 25% discount with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr Published on February 22, 2025 Category Dr. GPCR Courses In case you haven’t heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic Drugs,” with Dr. Terry Kenakin 👏 Spots are filling up fast, run and save yours, and enjoy a 25% discount with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Coffee Break 3 Date & Time Friday, November 3rd / 10:25 AM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Home → Flash News → The registration deadline for the 1-day workshop “The Practical Assessment of Signaling Bias” is TOMORROW! ⏰ Save your spot in a class with the Master of Pharmacology Dr. Terry Kenakin, and get 25% off with your Premium Membership. An advanced lecture, hands-on exercises, one private call with the professor, and more! ✳️Click here https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on February 17, 2025 Category Dr. GPCR Courses The registration deadline for the 1-day workshop “The Practical Assessment of Signaling Bias” is TOMORROW! ⏰ Save your spot in a class with the Master of Pharmacology Dr. Terry Kenakin, and get 25% off with your Premium Membership. An advanced lecture, hands-on exercises, one private call with the professor, and more! ✳️Click here https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → How do GRK-specific phosphorylation barcodes influence β-arrestin binding to GPCRs? New cryo-EM structures from Chen et al. (Nature, 2025) reveal that β-arrestin1 and β-arrestin2 form distinct complexes with ACKR3 depending on whether it's phosphorylated by GRK2 or GRK5, shaping arrestin conformation, complex stability, and engagement mode. Surprisingly, arrestin’s finger loop didn’t dive into the receptor core. Instead, it latched onto the micelle surface, breaking canonical expectations. Also, β-arrestin2 lacks a membrane anchor, making it more dynamic — a potential clue to its functional specialization. These findings underscore how barcode location + arrestin isoform = unique signaling outcomes. open book Read the full study: Inside Out: Mapping GPCRs from Membrane Codes to Market Moves #GPCRs #Arrestin #ACKR3 #GRKs #CryoEM #StructuralBiology #SignalingBias #Phosphorylation #DrGPCR Published on June 9, 2025 Category GPCR Weekly News How do GRK-specific phosphorylation barcodes influence β-arrestin binding to GPCRs? New cryo-EM structures from Chen et al. (Nature, 2025) reveal that β-arrestin1 and β-arrestin2 form distinct complexes with ACKR3 depending on whether it's phosphorylated by GRK2 or GRK5, shaping arrestin conformation, complex stability, and engagement mode. Surprisingly, arrestin’s finger loop didn’t dive into the receptor core. Instead, it latched onto the micelle surface, breaking canonical expectations. Also, β-arrestin2 lacks a membrane anchor, making it more dynamic — a potential clue to its functional specialization. These findings underscore how barcode location + arrestin isoform = unique signaling outcomes. Read the full study: Inside Out: Mapping GPCRs from Membrane Codes to Market Moves #GPCRs #Arrestin #ACKR3 #GRKs #CryoEM #StructuralBiology #SignalingBias #Phosphorylation #DrGPCR Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → A new study from the Hudson Lab at the University of Glasgow shows that the FFA receptor antagonist AH7614 is actually an inverse agonist - suppressing fat cell formation, boosting lipolysis and reducing glucose uptake. Explore how targeting FFA4 could help fight metabolic disorders. Catch up with the latest research conducted in the Hudson lab in Ep. 161 of the Dr. GPCR Podcast. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/inverse-agonism-of-the-ffa4-free-fatty-acid-receptor-controls-both-adipogenesis-and-mature-adipocyte-function #GPCR #drGPCR #FFA4 #metabolism #adipocytes” Published on April 7, 2025 Category GPCR Weekly News A new study from the Hudson Lab at the University of Glasgow shows that the FFA receptor antagonist AH7614 is actually an inverse agonist - suppressing fat cell formation, boosting lipolysis and reducing glucose uptake. Explore how targeting FFA4 could help fight metabolic disorders. Catch up with the latest research conducted in the Hudson lab in Ep. 161 of the Dr. GPCR Podcast. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https:// www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/inverse-agonism-of-the-ffa4-free-fatty-acid-receptor-controls-both-adipogenesis-and-mature-adipocyte-function #GPCR #drGPCR #FFA4 #metabolism #adipocytes Previous Next Recent Articles

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule "Have a nice weekend, and I'll see you tomorrow!": RAMP-interacting GPCR Pathways Date & Time Thursday, November 2nd / 4:30 PM Keynote Talk Abstract Coming Soon About Kathleen Caron "Kathleen M. Caron, Ph.D. is the Frederik L. Eldridge Distinguished Professor and Chair of the Department of Cell Biology & Physiology at The University of North Carolina at Chapel Hill—a large, interdisciplinary basic science department consistently ranked in the Top 5 in the Nation in NIH funding. Dr. Caron received a BS in Biology and BA in Philosophy at Emory University and a PhD at Duke University while training with Dr. Keith Parker to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models. She pursued postdoctoral training with Nobel Laureate Dr. Oliver Smithies at UNC-CH, where she was the first to discover the essential role of adrenomedullin peptide for embryonic survival. With a special emphasis on G protein coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease, preeclampsia and sex-dependent cardiovascular disease. Dr. Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, an Established Investigator Award and an Innovator Award from the American Heart Association, a Jefferson Pilot Award in Biomedical Sciences and a UNC-CH Mentoring Award. She currently serves as Associate Editor of Physiological Reviews; the #1 ranked journal in Physiology (IF 46.5). Dr. Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology and Translational Science. Dr. Caron currently holds multiple scientific advisory roles in academia, industry and the National Institutes of Health." Kathleen Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer Center Twitter Google Scholar ORCID ResearchGate Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization reframed her view of receptor pharmacology. Home → Flash News → where signaling happens inside a cell Why does it matter where signaling happens inside a cell? Published on November 13, 2025 Category Dr.GPCR Podcast Why does it matter where signaling happens inside a cell? This moment cuts straight to the heart of how many of us fell in love with GPCR biology — that realization that signaling isn’t random. It’s structured, organized, and spatially constrained. Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization reframed her view of receptor pharmacology. This shift — from thinking about “pathways” to understanding localized signaling architecture — is what drove her to build a research career around spatial control of GPCR signaling. This isn’t just academic. The way signals are organized defines specificity, drug response, and potential for targeted therapies. If you work with GPCRs, this perspective changes how you design experiments and interpret data. 🎧 Watch this insight — or listen to the full conversation with Michelle.🔗 Full episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling ✨ Join Premium: https://www.ecosystem.drgpcr.com/gpcr-university-pricing #GPCR #DrGPCR Previous Next Recent Articles

Home → Flash News → Ben Clements reveals a 10x improvement in efficacy using GPCR-targeted PAMs, in Ep.166 of the Dr.GPCR Podcast,. The catch? It’s all about understanding the system, not replacing it. From neuromas to novel modulators, this episode is full of breakthroughs that matter for patients. 📲 Watch now: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Published on May 22, 2025 Category Dr. GPCR Podcast Ben Clements reveals a 10x improvement in efficacy using GPCR-targeted PAMs, in Ep.166 of the Dr.GPCR Podcast,. The catch? It’s all about understanding the system, not replacing it. From neuromas to novel modulators, this episode is full of breakthroughs that matter for patients. 📲 Watch now: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025